← All stocks

ADIAL PHARMACEUTICALS, INC.

ADIL Net selling
CIK 0001513525 #5135 in the set updated 18 Sep 2026
Bought (120 mo)
$559.05K
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$948.50K
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$948.50K
4 of 4 sales
Net
−$389.45K
−$389.45K against sales at will

By person

11 insiders · 33 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Johnson Bankole A.
Director
$240.61K (5)
$948.50K (4)
−$707.89K
872,720
$2.40M
−39.1%
Newman James W. Jr.
Director
$122.57K (9)
+$122.57K
313,107
$861.04K
+375.1%
Coastlands Capital LP entity
10% owner
$106.33K (5)
+$106.33K
388,308
$1.07M
+11.5%
Stilley William B. III
Director
$87.62K (5)
+$87.62K
1,393,920
$3.83M
+132.4%
Schuyler Kevin
Director
$1.92K (2)
+$1.92K
126,055
$346.65K
+450.5%
Gilliland Robertson H.
Director
(1)
$0.00
118,609
$326.17K
+81.1%
Goodman Tony
Chief Operating Officer
(1)
$0.00
26,523
$72.94K
Davidson Matt
Chief Development Officer
300,918
$827.52K
+19,914%
Truluck Joseph
Chief Financial Officer
265,139
$729.13K
+255.3%
Claiborne Cary J
Chief Executive Officer
40,417
$111.15K
Shah Vinay
Chief Financial Officer
17,325
$47.64K

No percentages here. This company's share count has moved by a factor of 16.8 over the window, from 1,427,970 to 23,987,587 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 97
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 1
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 4
Transactions with no price 8
Shares from compensation/vesting 4,157,905
Sales filed before the plan box existed 4
History held since 2 Aug 2018